Skip to main content
Premium Trial:

Request an Annual Quote

BCW Index Drops Along with Broader Stock Market

The BCW Index fell 1.9 percent for the five-day trading period ended Tuesday, mirroring a drop in the broader stock market. For the tracking period, the Dow Jones Industrial Average fell 1.5 percent, the Nasdaq declined 1.6 percent, and the Nasdaq Biotech Index dropped 2.6 percent.
 
Fourteen of the 15 companies in the Index lost value, with Qiagen and Bruker BioSciences both falling 4 percent to lead decliners for the week. Stratagene was the only firm to gain ground, closing up 2.6 percent for the week.

 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Current Price
(November 28, 2006)
Last
Price
(November 20, 2006)
% change
Agilent A
32.60
33.74
-3.4
Applied Biosystems ABI
36.32
36.81
-1.3
Beckman BEC
59.00
59.92
-1.5
Bio-Rad BIO
78.96
80.42
-1.8
Bruker BRKR
7.59
7.91
-4.0
GE GE
35.20
35.98
-2.2
Invitrogen IVGN
55.45
57.24
-3.1
Millipore MIL
67.95
68.64
-1.0
Molecular Devices MDCC
20.72
21.39
-3.1
PerkinElmer PKI
21.10
21.51
-1.9
Qiagen QGEN
14.24
14.83
-4.0
Sigma SIAL
75.96
76.97
-1.3
Stratagene STGN
7.40
7.21
2.6
Thermo TMO
43.69
43.84
-0.3
Waters WAT
49.43
50.74
-2.6
BCW Index Average  
40.37
41.14
-1.9
The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.